When she heard about a new, experimental drug to treat pancreatic cancer, Rachelle Gardner tried not to get her hopes up. She wondered: Would she be eligible for the medication? Would her hospital be ...

In the early stages of pancreatic cancer, many people don't notice any symptoms or complications. Noticeable symptoms usually start after the cancer begins to affect how the pancreas functions or when ...

If you have pancreatic cancer that can't be cured, it makes sense that you wouldn't want to miss out on a medication that could help you slow the disease's spread. Treatments approved by the FDA or ...

“She was only 61 and very healthy,” said Allan Knight of his mother Judy, who was diagnosed and died of pancreatic cancer in 2007. “I did one search and the survival rates were in the single digits. I ...

A new experimental drug may offer hope for pancreatic cancer patients. One of deadliest types of cancer in the United States, an estimated 52,740 Americans will die from the disease this year, ...

Data from a major breakthrough in the fight against pancreatic cancer was released this month, highlighting a new pill that targets the root cause of how the disease exists and spreads. Arizona ...

The Food and Drug Administration today approved daraxonrasib to treat the most common form of pancreatic cancer. It's the first treatment to substantially extend the lives of patients diagnosed with ...

Dos expertas en este tumor analizan este "éxito sin precedentes" con daraxonrasib, una nueva molécula que se dirige a la vía esencial en cáncer de páncreas: la del oncogén KRAS. El cáncer de páncreas ...

A new, experimental medication nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a study published Sunday. Researchers say the findings ...

A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several ...

An experimental drug nearly doubled the overall survival rates of pancreatic cancer patients, according to the results of its latest clinical trial. The drug, daraxonrasib, targets the gene mutation ...